For the quarter ended March 2024, Qiagen (QGEN) reported income of $458.8 million, down 5.5% over the identical interval final yr. EPS got here in at $0.46, in comparison with $0.53 within the year-ago quarter.
The reported income represents a shock of +0.73% over the Zacks Consensus Estimate of $455.5 million. With the consensus EPS estimate being $0.44, the EPS shock was +4.55%.
Whereas buyers intently watch year-over-year adjustments in headline numbers — income and earnings — and the way they examine to Wall Avenue expectations to find out their subsequent plan of action, some key metrics at all times present a greater perception into an organization’s underlying efficiency.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps buyers venture a inventory’s worth efficiency extra precisely.
Right here is how Qiagen carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Avenue analysts:
- Gross sales by Product Teams- Diagnostic solutions- QIAstat-Dx: $25 million versus $23.82 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +19.1% change.
- Gross sales by Product Teams- Diagnostic solutions- QuantiFERON: $101 million versus $105.61 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +9.8% change.
- Gross sales by Product Teams- Genomics / NGS: $55 million versus $50.95 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a 0% change.
- Gross sales by Product Teams- Different: $11 million versus $11.67 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a -35.3% change.
- Gross sales by Product Teams- PCR / Nucleic acid amplification: $68 million versus $70.87 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a -11.7% change.
- Gross sales by Product Teams- Diagnostic solutions- NeuMoDx: $9 million versus $11.44 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a -30.8% change.
- Gross sales by Product Teams- Pattern applied sciences: $155 million versus $146.53 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a -10.4% change.
- Gross sales by Product Teams- Diagnostic options: $170 million versus the three-analyst common estimate of $174.25 million. The reported quantity represents a year-over-year change of +4.3%.
- Income- Life Sciences: $215 million versus $208.53 million estimated by two analysts on common.
- Gross sales by Product Teams- Diagnostic solutions- Different: $35 million versus the two-analyst common estimate of $35.07 million.
- Income- Molecular Diagnostics: $244 million in comparison with the $247.55 million common estimate primarily based on two analysts. The reported quantity represents a change of -2.4% yr over yr.
View all Key Company Metrics for Qiagen here>>>
Shares of Qiagen have returned -3.1% over the previous month versus the Zacks S&P 500 composite’s -2% change. The inventory at present has a Zacks Rank #4 (Promote), indicating that it might underperform the broader market within the close to time period.
Solely $1 to See All Zacks’ Buys and Sells
We’re not kidding.
A number of years in the past, we shocked our members by providing them 30-day entry to all our picks for the entire sum of solely $1. No obligation to spend one other cent.
Hundreds have taken benefit of this chance. Hundreds didn’t – they thought there should be a catch. Sure, we do have a motive. We wish you to get acquainted with our portfolio companies like Shock Dealer, Shares Beneath $10, Expertise Innovators,and extra, that closed 228 positions with double- and triple-digit positive factors in 2023 alone.
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
